Commercial applications of genomics to cancer are expected to make up a significant part of the predicted annual $22 billion global market for genomics by 2024.
This funding is part of the ISCF’s £210 million Data to Early Diagnosis and Precision Medicine Challenge. The challenge aims to fund researchers and industry to combine data and real-world evidence from UK health services and create new products and services that diagnose diseases earlier and more efficiently.
The competition aims to encourage new targeted cancer treatments based on the molecular signatures of cancer.
Projects must use whole genome sequencing to analyse cancer and can adopt various approaches including development of reporting tools, identification of molecular signatures, identification of therapeutic targets, and new genetic signatures.
They can focus on one or more of:
The competition will support a range of work from short feasibility studies to partners working on larger research and development projects.